{"groups":[{"description":"Patients receive dasatinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nAntitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening\n\nDasatinib: Given PO\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPharmacological Study: Correlative studies","id":"FG000","title":"Group I (Dasatinib)"},{"description":"Patients receive sutinib malate PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nAntitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPharmacological Study: Correlative studies\n\nSunitinib: Given PO\n\nSunitinib Malate: Given PO","id":"FG001","title":"Group II (Sutinib Malate)"},{"description":"Patients receive sorafenib tosylate PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nAntitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPharmacological Study: Correlative studies\n\nSorafenib: Given PO\n\nSorafenib Tosylate: Given PO","id":"FG002","title":"Group III (Sorafenib Tosylate)"},{"description":"Patients receive ponatinib hydrochloride PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity\n\nAntitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPharmacological Study: Correlative studies\n\nPonatinib: Given PO\n\nPonatinib Hydrochloride: Given PO","id":"FG003","title":"Group IV (Ponatinib Hydrochloride)"},{"description":"Patients receive pacritinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nAntitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPacritinib: Given PO\n\nPharmacological Study: Correlative studies","id":"FG004","title":"Group V (Pacritinib)"},{"description":"Patients receive ruxolitinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nAntitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPharmacological Study: Correlative studies\n\nRuxolitinib: Given PO","id":"FG005","title":"Group VI (Ruxolitinib)"},{"description":"Patients receive idelalisib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nAntitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening\n\nIdelalisib: Given PO\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPharmacological Study: Correlative studies","id":"FG006","title":"Group VII (Idelalisib)"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"6"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"6"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}